VEGF score was a significant parameter of peritoneal recurrence. Conclusion. These results suggested that VEGF was correlated with peritoneal metastasis from gastric cancer, and that VEGF was a useful indicator of peritoneal recurrence.
Introduction
In gastric cancer, the management of dissemination in the peritoneal cavity is extremely important. However, peritoneal dissemination at the final stage of gastric cancer remains untreatable. Peritoneal dissemination involves several steps, including tumor-cell attachment, invasion, and growth in the peritoneum. Many cytokines, growth factors, matrix metalloproteinases (MMPs), and angiogenic factors play important roles in these steps. Angiogenesis plays an important role in embryogenesis and tumorigenesis. So far, few studies have investigated the correlation, if any, between peritoneal dissemination and the angiogenic factor, vascular endothelial growth factor (VEGF). VEGF has been reported to enhance the permeability of tumor vessels [1] , to induce serine protease or metalloproteases [2, 3] , and to inhibit the apoptosis of endothelial cells [4, 5] and the maturation of dendritic cells [6] .
The aim of the present study was to clarify the significance of VEGF in peritoneal metastasis of gastric cancer. VEGF was analyzed, using immunohistochemical staining on slides of surgical specimens.
1256 patients underwent curative resection in this period. There were 65 patients with stage II gastric cancer with serosal invasion (T3N0H0P0M0), as defined in the Japanese classification of gastric carcinoma [7] .
Immunohistochemical analyses for VEGF and CD34 were performed on slides of the surgical specimens from 40 patients with stage II gastric cancer with serosal invasion who had no other neoplasm and who had undergone D2 or D3 lymph node dissection, excluding resection of multiple gastric cancer, and excluding resection of remnant stomach cancer. Twenty-four patients were men, and 16 were women. The mean age was 59.7 years, with age range from 35 to 79 years. There were 2 patients with macroscopic type IIc, 13 patients with type 2, 13 patients with type 3, and 12 patients with type 4.
Immunohistochemical staining
CD34 and VEGF were analyzed using immunohistochemical staining and the avidin-biotin-peroxidase complex technique (Vectastain ABC Kit; Vector, Burlingame, CA, USA). Briefly, paraffin sections were deparaffinized in xylene and rehydrated through graded ethanol solutions. The sections were washed with phosphate-buffered saline (PBS), treated with 0.3% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase, and then incubated with the primary antibody in a humidified chamber at 4°C overnight. As the primary antibody, the mouse monoclonal antibody QB-END/10 (BMA Biomedicals, Augst, Switzerland) for CD34, diluted at 1 : 10, and the rabbit polyclonal antibody A-20 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for VEGF, diluted at 1 : 200, were used. Sections were washed three times with PBS, then incubated with biotinylated horse antimouse/anti-rabbit immunoglobulin G antibody for 30 min, washed again three times with PBS, and then incubated with avidin-biotinylated peroxidase complex for 30 min. After three additional washings with PBS, staining was developed by incubating the sections in 3-amino-9-ethylcarbazole (Vector) for 5 min. The sections were then counterstained with hematoxylin and mounted.
Tumor vessels
Immunoreactivity of CD34 was recognized in the endothelium. Positive staining of small tubule-like formation for CD34 was defined as a microvessel. Vessels that were recognized along the invasive cancer nests or cancer cells were counted. The tumor vessel count was defined as the mean number of tumor vessels in a 400-times magnified field from ten arbitrary microscopic fields.
VEGF score
The cell types showing positive staining for VEGF were defined morphologically by H&E staining, using the serial sections. VEGF expression was classified as one of four categories, depending on the percentage of tumor cells stained (P): category 1, less than 25% of cells stained; category 2, from 25% to 49% stained; category 3, from 50% to 74% stained; and category 4, 75% or more cells stained. VEGF expression was also classified as one of three categories depending on the staining intensity (I): 1, weak; 2, moderate; 3, strong. A VEGF expression score was calculated, as P ¥ I. A pathologist confirmed the staining intensity of the tumor cells. A patient for whom the VEGF score was higher than the mean VEGF score was defined as being in the VEGF high-expression group, while all other patients for whom the VEGF score was lower than the mean VEGF score, were defined as being in the VEGF lowexpression group.
Statistical analysis

Student's t-test and the c
2 test were used to analyze the data for significant differences, and any difference was considered statistically significant when the P value was less than 0.05. The cumulative survival rate was calculated with the Kaplan-Meier method. The significance of any difference between the survival curves was determined using the Cox-Mantel test, and any difference was considered significant at the 5% level. Various factors, including age, sex, tumor size, type of lymph node dissection, macroscopic type, histological type, venous invasion, number of tumor vessels, and VEGF score were evaluated, by univariate analysis, for any independent contributions to peritoneal recurrence, using Fisher's exact test or the c 2 test. Significant factors were extracted for further analysis, carried out using multivariate analysis with a logistic regression method. The statistical analyses were performed using a statistical analysis computer program (Stat View 5.0; SAS Institute, Cary, NC, USA). The P value level of significance was set at 0.05.
Results
Patients
There were ten patients with peritoneal recurrence; the peritoneal recurrence was recognized as being type 4 in seven patients, and type 3 in the other three (Table 1) . No recurrence was seen in lymph nodes or in the liver, in any patient (Table 1) .
Immunohistochemical staining
Immunoreactivity for CD34 was recognized in the endothelium (Fig. 1 ). Immunoreactivity for VEGF was mainly identified as supranuclear staining or diffused staining in the cytoplasm of cancer cells (Fig. 2) , and VEGF was observed in some epithelial cells, lymphocytes, and macrophages. The incidence of patients with peritoneal recurrence according to the percentage of positive tumor staining (P) was 85.7% (6/7) in category 4, 50% (4/8) in category 3, and 0% in both category 2 (0/17) and category 1 (0/8; Table 2 ). The incidence of peritoneal recurrence in category 4, and in category 3, was significantly higher than that in category 2 (P < 0.001; P < 0.01, respectively). The incidence of peritoneal recurrence in category 4 was significantly higher than that in category 1 (P < 0.005; Table 2 ). The incidence of peritoneal recurrence according to staining intensity (I) was 60.0% (6/10) in those with strong intensity, 23.5% (4/17) in those with moderate intensity, and 6/10 (60.0)* P: * P < 0.001 vs м25% and <50%, * P < 0.005 vs <25%, ** P < 0.01 vs м25% and <50% I: * P < 0.01 vs weak; * P < 0.05 vs moderate 0% (0/13) in those with weak staining intensity ( Table  2 ). The incidence of peritoneal recurrence in those with strong intensity was significantly higher than that in those with moderate or weak intensity (P < 0.05; P < 0.01, respectively; Table 2 ). Based on the VEGF expression score according to the criteria P ¥ I, VEGF high expression was found in 16 patients, and low expression in 24 (Table 3 ). In patients with type 3 or type 4, VEGF high expression was found in 11, and low expression in 14 (Table 3 ). In patients with type 4, VEGF high expression was found in 7, and low expression in 5 (Table 3) .
Tumor vessels
The mean number of tumor vessels involved in macroscopic type IIc, type 2, type 3, and type 4 cancers was 24.0 ± 5.09, 18.0 ± 5.99, 24.9 ± 6.02, and 27.2 ± 11.9, respectively ( Table 4 ). The mean number of tumor vessels in type 3 or type 4 was significantly higher than that in type 2 (P < 0.01, and P < 0.05, respectively). The mean number of tumor vessels in patients with peritoneal recurrence was 28.9 ± 12.7, and that in patients without peritoneal recurrence was 22.5 ± 5.65 (Table 5 ). In patients with type 3 or type 4, the mean number of tumor vessels in those with peritoneal recurrence was 28.9 ± 12.7, and that in those without peritoneal recurrence was 24.1 ± 5.61 (Table 6 ). In patients with type 4, the mean number of tumor vessels in those with peritoneal recurrence was 29.8 ± 14.8, and that in those without peritoneal recurrence was 23.6 ± 5.85 (Table 7) . There was no significant correlation between the number of tumor vessels and peritoneal recurrence.
Venous invasion
The rate of venous invasion in patients with type IIc, type 2, type 3, and type 4, was 0% (0/2), 61.5% (8/13), (Table 4) . There was no significant difference in this rate among the various macroscopic types. The rate of venous invasion in patients with peritoneal recurrence was 60.0% (6/10), and that in patients without peritoneal recurrence was 46.7% (14/30; Table 5 ). In patients with type 3 or type 4, the rate of venous invasion in those with peritoneal recurrence was 60.0% (6/10), and that in those without peritoneal recurrence was 40.0% (6/15; Table 6 ). In patients with type 4, the rate of venous invasion in those with peritoneal recurrence was 57.1% (4/7), and that in those without peritoneal recurrence was 0% (0/5; Table 7) , with no significant correlation between the rate of venous invasion and peritoneal recurrence.
The VEGF score
The VEGF score in patients with type IIc, type 2, type 3, and type 4 was 2.00 ± 0.00, 2.92 ± 1.71, 5.62 ± 3.80, and 6.92 ± 3.68, respectively ( Table 4 ). The VEGF score in patients with type 3 or type 4 was significantly higher than that in patients with type 2 (P < 0.05, both). The VEGF score in patients with peritoneal recurrence was 9.40 ± 2.46, and that in those without peritoneal recurrence was 3.47 ± 2.36 (Table 5 ). In patients with type 3 or type 4, the VEGF score in those with peritoneal recurrence was 9.40 ± 2.46, and that in those without peritoneal recurrence was 4.13 ± 2.83 (Table 6 ). In patients with type 4, the VEGF score in those with peritoneal recurrence was 9.14 ± 2.19, and that in those without peritoneal recurrence was 3.80 ± 3.03 (Table 7) ; the VEGF score in patients with peritoneal recurrence was significantly higher than that in patients without peritoneal recurrence (P < 0.001). In patients with type 3 or type 4, and separately in those with type 4, the VEGF score in patients with peritoneal recurrence was significantly higher than that in those without peritoneal recurrence (P < 0.001; P < 0.05, respectively).
The number of tumor vessels and VEGF expression
The mean number of tumor vessels in the VEGF highexpression group was 27.3 ± 11.4, and that in the VEGF low-expression group was 21.9 ± 4.83 (Table 8 ). The mean number of tumor vessels in the VEGF highexpression group tended to be higher than that in the VEGF low-expression group. In patients with type 3 or type 4, the mean number of tumor vessels in the VEGF high-expression group was 28.0 ± 12.2, and that in the VEGF low-expression group was 24.5 ± 6.01 (Table 9) , with no significant difference between the VEGF high- expression group and the VEGF low-expression group. In patients with type 4, the mean number of tumor vessels in the VEGF high-expression group was 32.1 ± 13.6, and that in the VEGF low-expression group was 20.4 ± 3.14 (Table 10) , with the mean number of tumor vessels in the VEGF high-expression group tending to be higher than that in the VEGF low-expression group.
Venous invasion and VEGF expression
The rate of venous invasion in the VEGF highexpression group was 56.3% (9/16), and that in the VEGF low-expression group was 45.8% (11/24; Table 8 ). In patients with type 3 or type 4, the rate of venous invasion in the VEGF high-expression group was 54.5% (6/11) , and that in the VEGF low-expression group was 28.6% (4/14; Table 9 ). In patients with type 4, the rate of venous invasion in the VEGF highexpression group was 42.9% (3/7), and that in the VEGF low-expression group was 20.0% (1/5; Table 10) , with no significant correlation between the rate of venous invasion and VEGF expression. 
Multivariate analysis
Multivariate analysis was conducted for the three parameters (sex, macroscopic type, and VEGF score) that had been found to be significant by univariate analysis (Table 11 ). The multivariate analysis showed that the VEGF score, and the macroscopic type, but not sex, were significant parameters of peritoneal recurrence (Table 11) .
Survival curves
The 5-year-survival rate was 90.0% in the VEGF low-expression group, and 26.3% in the VEGF highexpression group. The survival curve in the VEGF lowexpression group was significantly higher than that in the VEGF high-expression group ( Fig. 3 ; P < 0.01).
In patients with type 3 or type 4, the 5-year-survival rate was 65.2% in the VEGF low-expression group, and 20.5% in the VEGF high-expression group. The survival curve in the VEGF low-expression group was significantly higher than that in the VEGF highexpression group ( Fig. 4 ; P < 0.05). In patients with type 4, the 5-year survival rate was 75.0% in the VEGF low-expression group, and 14.3% in the VEGF highexpression group; the survival curve in the VEGF lowexpression group tended to be higher than that in the VEGF high-expression group, but there was no significant difference (Fig. 5) .
Discussion
Scirrhous carcinoma of the stomach, known as diffusely infiltrative carcinoma or Borrman's type-IV carcinoma, or linitis plastica-type carcinoma, is characterized clinically as having the worst prognosis among the various types of gastric cancer, because it is frequently associated with metastases to lymph nodes and with peritoneal dissemination. The mechanism of peritoneal dissemination has not yet been clearly defined. Many reports have suggested that it occurs via the attachment of free cancer cells to the peritoneum [8] [9] [10] . So far, few studies have investigated the correlation, if any, between cancer cells and mesothelial cells during proliferation following attachment. Angiogenesis is a key component in various steps of human cancer development and spread [11] . Previous reports have indicated that the presence of angiogenic factors is an essential event in the development of peritoneal metastasis [12] [13] [14] . VEGF, as well as functioning as a growth factor, is also able to function as a vascular permeability factor. Increased permeability of blood vessels facilitates the extravasation of proteins and the formation of ascites [15] [16] [17] . In previous reports, the expression level of VEGF has been found to be directly associated with the Fig. 3 . The survival curve of the VEGF low-expression group was significantly higher than that of the VEGF highexpression group (P < 0.01) Fig. 4 . Survival curves for patients with macroscopic type 3 and type 4 cancers. The survival curve of the VEGF lowexpression group was significantly higher than that of the VEGF high-expression group (P < 0.05) Fig. 5 . Survival curves for patients with macroscopic type 4 cancer. The survival curve of the VEGF low-expression group tended to be higher than that of the VEGF high-expression group, but with no significant difference. N.S, not significant production of ascites and carcinomatosis [17, 18] . Indeed, Kraft et al. [19] reported that VEGF may play an important role in tumor progression and the formation of malignant effusions. Mesiano et al. [20] demonstrated that the neutralization of VEGF activity may have clinical applications in inhibiting malignant ascites formation in ovarian cancer. Cancer cells transfected with VEGF have shown an increased potential for the development of tumorigenesis in a xenograft model [13] . Moreover, the functional inhibition of VEGF by neutralizing monoclonal antibody to VEGF [20] or by soluble VEGF receptor (R)-1 [14] effectively suppressed the development of peritoneal dissemination. In addition, VEGF levels were markedly elevated in malignant ascites [21] . We have found that the VEGF level in the medium of a gastric cancer cell line with a high potential for peritoneal metastasis was significantly higher than that in a gastric cancer cell line with a low potential for peritoneal metastasis (data not shown). These studies have provided clear evidence that VEGF is an essential element in the development of peritoneal metastasis. Tokuhara et al. [22] multiplied the proportion of VEGF-stained cells by the intensity of VEGF staining to evaluate VEGF expression in colorectal cancer, and they discovered a significant positive correlation between the vascular expression of E26 transformation-specific-1 (Ets-1), which influences angiogenesis, and VEGF, or pyrimidine nucleoside phosphorylase (dThdPase) activity in the tumor. In the present study, not only the percentage of tumor cells stained for VEGF but also the staining intensity was correlated with peritoneal recurrence, Therefore, we included the degree of staining intensity of VEGF, to calculate the VEGF score, in the 40 patients with stage II gastric cancer with serosal invasion that we investigated. No recurrence was recognized in any lymph node or in the liver in any of the patients. Peritoneal recurrences were recognized in patients with macroscopic type 4 or type 3, but were not recognized in those with type 2 or type IIc. The VEGF score of patients with type 3 or type 4 was significantly higher than that in patients with type 2. The VEGF score in patients with peritoneal recurrence was significantly higher than that in those without peritoneal recurrence. Even in patients with type 4, the VEGF score in those with peritoneal recurrence was significantly higher than that in patients without peritoneal recurrence. These results suggested that the VEGF score was a useful marker. Moreover, multivariate analysis showed that the VEGF score was a significant indicator of peritoneal recurrence. Therefore, we speculate that treatment with VEGF antibody might prevent peritoneal recurrence of gastric cancer. Konno et al. [23] reported that, in gastric cancer patients, VEGF levels in the peripheral veins were higher in patients with venous invasion. In our study, the mean number of tumor vessels patients with in type 3 or type 4 was significantly higher than that in patients with type 2, and the mean number of tumor vessels in those with high expression of VEGF tended to be greater than that in those with low VEGF expression. These results suggested that the expression of VEGF in tumor cells was correlated with the number of tumor vessels. The incidence of venous invasion in patients with high expression of VEGF was higher than that in patients with low expression of VEGF, but without significance. If a larger number of patients were to be studied, VEGF might be found to be significantly correlated with the incidence of venous invasion.
